Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine

Blasko, Imrich; Jellinger, K. A.; Kemmler, Georg; Krampla, Wolfgang; Jungwirth, Susanne; Wichart, Ildigo; Tragl, Karl Heinz; Fischer, Peter

doi:10.1016/j.neurobiolaging.2006.09.002

Cited by 121 publications

(96 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a growing consensus that changes in blood Aβ levels parallel AD onset and progression, although these findings remain discrepant with respect to specific species, that is, Aβ or Aβ 1-40 (2)(3)(4)(5)(6). Despite this discrepancy, evidence is now emerging in favor of the more pathologic form, Aβ , being elevated at the stage of mild cognitive impairment or an even earlier prodromal stage of AD, possibly owing to increased production (2,5,7).…”

Section: H I G H a β I N R E L A T I V E S O F A D P A T I E N T Smentioning

confidence: 99%

“…Among AD patients, an initial increase in blood Aβ 1-42 is followed by a decrease (2), and an increase in Aβ over time was shown to be a significant predictor of conversion to mild cognitive impairment or AD (5). More recently, Aβ was shown to be higher in patients with mild cognitive impairment compared with both AD patients and controls (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer’s Disease Patients

Abdullah

Luis

Paris

et al. 2009

Mol Med

View full text Add to dashboard Cite

The main objective of this study was to determine whether elevated blood β-amyloid (Aβ) levels among the first-degree relatives of patients with Alzheimer's Disease (AD) are associated with vascular risk factors of AD. Serum Aβ was measured in samples from 197 cognitively normal first-degree relatives of patients with AD-like dementia. Study participants were recruited as part of an ancillary study of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT subpopulation). The ADAPT subpopulation was found to be similar in age, sex, and ethnicity to another cognitively normal cohort (n = 98). Using cross-sectional analyses, we examined the association of Aβ with blood pressure, lipid levels, apolipoprotein E genotypes, and the use of prescribed medication to treat vascular risk factors in the ADAPT subpopulation. Aβ 1-40 was positively associated with age, use of antihypertensives, and serum creatinine, and we observed a marginal negative interaction on Aβ 1-40 associated with systolic blood pressure and use of antihypertensives. Serum Aβ 1-42 was associated with statin use and a positive correlation of Aβ 1-42 with HDL was observed among statin nonusers. These findings suggest that high Aβ in the periphery among the family history-enriched cohorts may be due to enrichment of vascular risk factors and may reflect presymptomatic AD pathology. It remains to be determined whether the association of Aβ with medications used for treating vascular risk factors indicates prevention of AD. Longitudinal evaluation of blood Aβ in this cohort will provide a better understanding of the significance of this association in AD etiology.

show abstract

Section: H I G H a β I N R E L A T I V E S O F A D P A T I E N T Smentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer’s Disease Patients

Abdullah

Luis

Paris

et al. 2009

Mol Med

View full text Add to dashboard Cite

show abstract

“…48,49 Increments in plasma Ab 42 have also been reported to predict AD in these subjects. 50,51 Many studies have not found significant differences in the concentrations of these biomarkers in samples of MCI converters. 52,53 Therefore, the current evidence suggests that measurement of plasma Ab as a biomarker for AD is still controversial and lacks the consistency observed for CSF biomarkers.…”

Section: Peripheral Biomarkersmentioning

confidence: 99%

Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

Forlenza

Diniz

Teixeira

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings.

show abstract

“…However, A 1-40 levels are not specific for AD and in fact are affected by age (Luchsinger et al, 2007 enough, correlation with neuroimages or other biological markers is needed (Blasko et al 2008). Other metabolic and nutritional markers have also been studied, including levels of folic acid and vitamin B12 but results are conflicting so far (Irizarry et al 2005;Isobe et al 2005;Köseoglu & Karaman 2007;Serot et al 2005;Seshadri et al 2002).…”

Section: Peripheral Biomarkersmentioning

confidence: 99%

In Search of Therapeutic Solutions for Alzheimer’s Disease

Maccioni¹,

Farías²,

Rojo³

et al. 2012

When Things Go Wrong - Diseases and Disorders of the Human Brain

View full text Add to dashboard Cite

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine

Cited by 121 publications

References 51 publications

High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer’s Disease Patients

High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer’s Disease Patients

Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

In Search of Therapeutic Solutions for Alzheimer’s Disease

Contact Info

Product

Resources

About